Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities

Abstract

DNA damage often activates the p53–p21 pathway and causes G1-phase arrest in mammalian cells. Although there is ample evidence that p21 induction by p53 leads to Cdk2 inhibition, it is unclear whether this checkpoint event also leads to Cdk4 inhibition. Diaminocyclohexane(trans-diacetato)(dichloro) platinum(IV) (DAP), a platinum-based coordination complex, is a DNA-damaging agent that is effective against a variety of tumor cells resistant to the parental drug cisplatin. Our previous studies established that treatment of human cancer cells with low effective concentrations of DAP specifically activates the G1-phase checkpoint and simultaneously inhibit Cdk4 and Cdk2 activities. Here we demonstrate that DAP treatment of human cancer cells activates the p53–p21 pathway without activating other known mechanisms that inhibit Cdk4 and Cdk2 activities. The induced p21 binds to both the Cdk4/cyclin D and Cdk2/cyclin E complexes and inhibits both of their kinase activities. Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities. Attenuated p53 expression and p21 induction also eliminates DAP-induced G1-phase arrest and inhibition of Cdk4 and Cdk2 activities. Together, these findings establish that activation of the p53–p21 pathway is responsible for the DAP-induced G1-phase checkpoint response and provide the first solid evidence that p21 induction by p53 during a DNA damage-induced G1-phase checkpoint response inhibits both Cdk4 and Cdk2 activities.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11

Similar content being viewed by others

References

  • Agami R and Bernards R . (2000). Cell, 102, 55–66.

  • Agami R and Bernards R . (2002). Cancer Lett., 177, 111–118.

  • Attardi LD, de Vries A and Jacks T . (2004). Oncogene, 23, 973–980.

  • Bagui TK, Jackson RJ, Agrawal D and Pledger WJ . (2000). Mol. Cell. Biol., 20, 8748–8757.

  • Bagui TK, Mohapatra S, Haura E and Pledger WJ . (2003). Mol. Cell. Biol., 23, 7285–7290.

  • Bartek J and Lukas J . (2001a). Curr. Opin. Cell Biol., 13, 738–747.

  • Bartek J and Lukas J . (2001b). FEBS Lett., 490, 117–122.

  • Blasina A, Paegle ES and McGowan CH . (1997). Mol. Biol. Cell, 8, 1013–1023.

  • Boulaire J, Fotedar A and Fotedar R . (2000). Pathol. Biol. (Paris), 48, 190–202.

  • Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ . (1995). Nature, 377, 552–557.

  • Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T and Lees JA . (1999). Proc. Natl. Acad. Sci. USA, 96, 1002–1007.

  • Burger H, Nooter K, Boersma AW, Kortland CJ and Stoter G . (1998). Br. J. Cancer, 77, 1562–1567.

  • Buscemi G, Perego P, Carenini N, Nakanishi M, Chessa L, Chen J, Khanna K and Delia D . (2004). Oncogene, 23, 7691–7700.

  • Che S, El-Hodiri H, Wu C-F, Nelman-Gonzalez M, Weil MM, Etkin LD, Clark D and Kuang J . (1999). J. Biol. Chem., 274, 5522–5531.

  • Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ . (1999). EMBO J., 18, 1571–1583.

  • Cohen SM and Lippard SJ . (2001). Progress Nucleic Acid Res. Mol. Biol., 67, 93–130.

  • Datta R, Hass R, Gunji H, Weichselbaum R and Kufe D . (1992). Cell Growth Differ., 3, 637–644.

  • Deng C, Zhang P, Harper JW, Elledge SJ and Leder P . (1995). Cell, 82, 675–684.

  • Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI . (1994). Cell, 76, 1013–1023.

  • Dulic V, Lees E and Reed SI . (1992). Science, 257, 1958–1961.

  • Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH and Gribble GW . (2002a). Mol. Cancer Ther., 1, 1067–1078.

  • Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH and Gribble GW . (2002b). Mol. Cancer Ther., 1, 1067–1078.

  • el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE and Wang Y . (1994). Cancer Res., 54, 1169–1174.

  • Elledge SJ . (1996). Science, 274, 1664–1672.

  • Falck J, Mailand N, Syljuasen RG, Bartek J and Lukas J . (2001). Nature, 410, 842–847.

  • Girard F, Strausfeld U, Fernandez A and Lamb NJ . (1991). Cell, 67, 1169–1179.

  • Goldwasser F, Valenti M, Torres R, Kohn KW and Pommier Y . (1996). Clin. Cancer Res., 2, 687–693.

  • Gong J, Traganos F and Darzynkiewicz Z . (1995). Cell Growth Differ., 6, 1485–1493.

  • Gould KL and Nurse P . (1989). Nature, 342, 39–45.

  • Gu Y, Rosenblatt J and Morgan DO . (1992). EMBO J., 11, 3995–4005.

  • Hagopian GS, Mills GB, Khokhar AR, Bast Jr RC and Siddik ZH . (1999). Clin. Cancer Res., 5, 655–663.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . (1993). Cell, 75, 805–816.

  • Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP and Wei N . (1995). Mol. Biol. Cell, 6, 387–400.

  • Jiang H, Chou HS and Zhu L . (1998). Mol. Cell. Biol., 18, 5284–5290.

  • Jin P, Gu Y and Morgan DO . (1996). J. Cell Biol., 134, 963–970.

  • Khokhar AR, al-Baker S, Shamsuddin S and Siddik ZH . (1997). J. Med. Chem., 40, 112–116.

  • Kido Y, Khokhar AR, al-Baker S and Siddik ZH . (1993). Cancer Res., 53, 4567–4572.

  • Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts JM . (1992). Science, 257, 1689–1694.

  • Kuang J, He G, Huang Z, Khokhar AR and Siddik ZH . (2001). Clin. Cancer Res., 7, 3629–3639.

  • LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E . (1997). Genes Dev., 11, 847–862.

  • Lenferink AE, Busse D, Flanagan WM, Yakes FM and Arteaga CL . (2001). Cancer Res., 61, 6583–6591.

  • Li Y, Jenkins CW, Nichols MA and Xiong Y . (1994). Oncogene, 9, 2261–2268.

  • Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J and Lukas J . (2000). Science, 288, 1425–1429.

  • Miyakawa Y and Matsushime H . (2001). Biochem. Biophys. Res. Commun., 284, 71–76.

  • Morla AO, Draetta G, Beach D and Wang JY . (1989). Cell, 58, 193–203.

  • Muschel RJ, Zhang HB, Iliakis G and McKenna WG . (1991). Cancer Res., 51, 5113–5117.

  • Muschel RJ, Zhang HB, Iliakis G and McKenna WG . (1992). Radiat. Res., 132, 153–157.

  • Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, Levy J and Sharoni Y . (2001). Oncogene, 20, 3428–3436.

  • O'Connor PM . (1997). Cancer Surv., 29, 151–182.

  • Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G . (1992). EMBO J., 11, 961–971.

  • Perdiguero E, Pillaire MJ, Bodart JF, Hennersdorf F, Frodin M, Duesbery NS, Alonso G and Nebreda AR . (2003). EMBO J., 22, 5746–5756.

  • Pestell KE, Hobbs SM, Titley JC, Kelland LR and Walton MI . (2000). Mol. Pharmacol., 57, 503–511.

  • Petrocelli T, Poon R, Drucker DJ, Slingerland JM and Rosen CF . (1996). Oncogene, 12, 1387–1396.

  • Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J . (1994). Cell, 78, 59–66.

  • Poon RY and Hunter T . (1995). Science, 270, 90–93.

  • Poon RY, Jiang W, Toyoshima H and Hunter T . (1996). J. Biol. Chem., 271, 13283–13291.

  • Rhind N, Furnari B and Russell P . (1997). Genes Dev., 11, 504–511.

  • Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S . (2004). Annu. Rev. Biochem., 73, 39–85.

  • Serrano M, Hannon GJ and Beach D . (1993). Nature, 366, 704–707.

  • Shapiro GI, Edwards CD, Ewen ME and Rollins BJ . (1998). Mol. Cell. Biol., 18, 378–387.

  • Shapiro GI, Edwards CD and Rollins BJ . (2000). Cell Biochem. Biophys., 33, 189–197.

  • Sherr CJ . (1993). Cell, 73, 1059–1065.

  • Sherr CJ and Roberts JM . (1999). Genes Dev., 13, 1501–1512.

  • Siddik ZH . (2003). Oncogene, 22, 7265–7279.

  • Siddik ZH, al-Baker S, Thai G and Khokhar AR . (1994). Anticancer Drug Des., 9, 139–151.

  • Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP and Medema RH . (2000). J. Biol. Chem., 275, 30638–30643.

  • Strathdee G, Sansom OJ, Sim A, Clarke AR and Brown R . (2001). Oncogene, 20, 1923–1927.

  • Terada Y, Tatsuka M, Jinno S and Okayama H . (1995). Nature, 376, 358–362.

  • Toyoshima H and Hunter T . (1994). Cell, 78, 67–74.

  • Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J and Nikaido T . (1999). J. Biol. Chem., 274, 35809–35815.

  • Waldman T, Kinzler KW and Vogelstein B . (1995). Cancer Res., 55, 5187–5190.

  • Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA and O'Connor PM . (1996). J. Natl. Cancer Inst., 88, 956–965.

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D . (1993). Nature, 366, 701–704.

  • Ye XS, Fincher RR, Tang A and Osmani SA . (1997). EMBO J., 16, 182–192.

  • Zamble DB, Jacks T and Lippard SJ . (1998). Proc. Natl. Acad. Sci. USA, 95, 6163–6168.

  • Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC and Fornace AJ . (1999). Oncogene, 18, 2892–2900.

  • Zhao H and Piwnica-Worms H . (2001). Mol. Cell. Biol., 21, 4129–4139.

Download references

Acknowledgements

This work was supported by Public Health Service Grants CA-93941, CA-77332, and CA-82361 from the National Cancer Institute. We thank Dr MH Lee for providing p21 plasmid and Dr J Nakamura and P Hennessey for preparing and analysing DAP solutions. We also thank Dr Vogelstein for providing an isogenic pair of HCT-116 cells that differ only in p21 gene status.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jian Kuang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, G., Siddik, Z., Huang, Z. et al. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene 24, 2929–2943 (2005). https://doi.org/10.1038/sj.onc.1208474

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208474

Keywords

This article is cited by

Search

Quick links